Debananda Gogoi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Debananda Gogoi has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Emer Patricia Reeves
Royal College of Surgeons in Ireland Dublin, Ireland
10 shared publications - Ashis Kumar Mukherjee
Institute of Advanced Study in Science & Technology
8 shared publications - Luke Forde
Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, RCSI University of Medicine and Health Sciences , Dublin
6 shared publications - Rory Baird
Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, RCSI University of Medicine and Health Sciences , Dublin
6 shared publications - Mengxin Niu
Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, RCSI University of Medicine and Health Sciences , Dublin
4 shared publications - Sara Waqas Ahmed
Pulmonary Clinical Science, Department of Anaesthesia and Critical Care Medicine, RCSI University of Medicine and Health Sciences , Dublin
4 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Purinergic receptor remodelling in circulating and airway cells of patients with progressive fibrotic lung disease
- 23 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPurinergic receptor remodelling in circulating and airway cells of patients with progressive fibrotic lung disease
- Open Access
- 1 January 2026
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 18 (1) , 222-232
The Challenges of Detecting Neutrophil CFTR
Background: Cystic fibrosis (CF) is a hereditary disorder caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The major causes of morbidity and mortality in CF are related to lung disease, involving neutrophil-dominated lung inflammation. Summary: Whether the altered inflammatory response of neutrophils in patients with CF is an intrinsic defect due to a lack of CFTR protein expression, or alternatively, exacerbated by chronic exposure to infection and inflammation, is extensively debated. Fuelling this dispute are conflicting past studies on CFTR expression by neutrophils, with opposing results described at both the gene and protein level. This is pertinent in the era of CFTR modulator therapies, with clinicians and scientists exploring the impact of different CFTR mutation classes and CFTR modulators on neutrophil function. Key Messages: The focus of this article was to uncover the cause for the described disparity of data on neutrophil CFTR expression, by investigating methods utilised for CFTR detection and drawing consensus on the optimal protocol for identifying CFTR protein in neutrophils.
- 1 January 2026
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 18 (1) , 222-232
Open AccessThe Challenges of Detecting Neutrophil CFTR
Background: Cystic fibrosis (CF) is a hereditary disorder caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The major causes of morbidity and mortality in CF are related to lung disease, involving neutrophil-dominated lung inflammation. Summary: Whether the altered inflammatory response of neutrophils in patients with CF is an intrinsic defect due to a lack of CFTR protein expression, or alternatively, exacerbated by chronic exposure to infection and inflammation, is extensively debated. Fuelling this dispute are conflicting past studies on CFTR expression by neutrophils, with opposing results described at both the gene and protein level. This is pertinent in the era of CFTR modulator therapies, with clinicians and scientists exploring the impact of different CFTR mutation classes and CFTR modulators on neutrophil function. Key Messages: The focus of this article was to uncover the cause for the described disparity of data on neutrophil CFTR expression, by investigating methods utilised for CFTR detection and drawing consensus on the optimal protocol for identifying CFTR protein in neutrophils.
- Open Access
- 1 January 2026
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 18 (1) , 104-119
Inhibition of Pseudomonas aeruginosa Biofilm Formation by Peptidyl-Arginine Deiminases 2 and 4
Introduction: Pseudomonas aeruginosa is a significant pathogen associated with acute and chronic infections, particularly in immunocompromised individuals. Its capacity for biofilm formation, combined with antibiotic resistance, plays a critical role in the persistence of these infections. Peptidyl-arginine deiminases (PADs), including PAD2 and PAD4 isoforms, are involved in neutrophil phagocytic killing of P. aeruginosa. This study aimed to investigate the impact of PAD enzymes on biofilm development and virulence factor production in P. aeruginosa, with focus on the multidrug resistant strain, PGO2330. Methods: Biofilm formation was assessed using crystal violet assays and confocal scanning laser microscopy. Quorum sensing (QS) gene expression and QS-related virulence factor production were quantified using qPCR and virulence factor assays. Results: Exposure to 20 nm of PAD2 or PAD4 reduced PGO2330 surface attachment (p < 0.0001) and biofilm formation to 67.9 ± 5.6% (p < 0.0001) and 68.2 ± 4.2% (p = 0.0004), respectively. Moreover, rPAD2 and rPAD4 citrullinated multiple protein substrates of P. aeruginosa, yet citrullination activity was not required by rPADs to reduce P. aeruginosa biofilm formation. PGO2330 exposed to PAD2 and PAD4 showed reduced lasR, lasI, rhlR, rhlI, and mvfR gene expression and reduced levels of extracellular DNA, rhamnolipids, pyocyanin, and protease activity. Conclusion: These results demonstrate that PADs inhibit P. aeruginosa biofilm formation and decrease the production of QS-related virulence factors, highlighting their potential as novel antimicrobials and supporting further research into the development of PAD-based therapeutics.
- 1 January 2026
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 18 (1) , 104-119
Open AccessInhibition of Pseudomonas aeruginosa Biofilm Formation by Peptidyl-Arginine Deiminases 2 and 4
Introduction: Pseudomonas aeruginosa is a significant pathogen associated with acute and chronic infections, particularly in immunocompromised individuals. Its capacity for biofilm formation, combined with antibiotic resistance, plays a critical role in the persistence of these infections. Peptidyl-arginine deiminases (PADs), including PAD2 and PAD4 isoforms, are involved in neutrophil phagocytic killing of P. aeruginosa. This study aimed to investigate the impact of PAD enzymes on biofilm development and virulence factor production in P. aeruginosa, with focus on the multidrug resistant strain, PGO2330. Methods: Biofilm formation was assessed using crystal violet assays and confocal scanning laser microscopy. Quorum sensing (QS) gene expression and QS-related virulence factor production were quantified using qPCR and virulence factor assays. Results: Exposure to 20 nm of PAD2 or PAD4 reduced PGO2330 surface attachment (p < 0.0001) and biofilm formation to 67.9 ± 5.6% (p < 0.0001) and 68.2 ± 4.2% (p = 0.0004), respectively. Moreover, rPAD2 and rPAD4 citrullinated multiple protein substrates of P. aeruginosa, yet citrullination activity was not required by rPADs to reduce P. aeruginosa biofilm formation. PGO2330 exposed to PAD2 and PAD4 showed reduced lasR, lasI, rhlR, rhlI, and mvfR gene expression and reduced levels of extracellular DNA, rhamnolipids, pyocyanin, and protease activity. Conclusion: These results demonstrate that PADs inhibit P. aeruginosa biofilm formation and decrease the production of QS-related virulence factors, highlighting their potential as novel antimicrobials and supporting further research into the development of PAD-based therapeutics.
- 23 September 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (3) , 403-406
CFTR modulator therapy impacts neutrophil CD39 expression in cystic fibrosis
- 23 September 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (3) , 403-406
CFTR modulator therapy impacts neutrophil CD39 expression in cystic fibrosis
- Open Access
- 1 January 2025
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 17 (1) , 468-486
A Review of Proteases and Antiproteases for Immune Regulation and Potential Therapeutic Application in Pulmonary Fibrosis
Background: Interstitial lung diseases (ILDs) or diffuse parenchymal lung diseases are general terms for a group of over 200 conditions that result from the destruction of cells neighbouring the alveoli, leading to extensive inflammation and fibrosis of the lungs. Although different types of ILD have distinct pathophysiology, clinical display, and advancement, many forms drive irreversible pulmonary fibrosis (PF), leading to progressive functional impairment, respiratory failure, and mortality. Summary: Key components of innate immunity include proteases and their cognate inhibitors, which are involved in respiratory homoeostasis. Alterations to the protease-antiprotease balance can lead to pulmonary disease and fibrotic scarring of the lungs, and over the past two decades, there has been a surge in research exploring their effect on the pathogenesis of ILDs. We have evaluated relevant studies regarding these enzymes in the context of lung fibrosis and have discussed prospects for developing novel treatments. This review will place greater emphasis on the overall effect of proteases and antiproteases to the development of PF, as studied using both in vivo and in vitro models. Key Message: Considering the limited therapeutic interventions, continued research on proteolytic enzymes and their inhibitors is required for the development of novel effective treatments for PF.
- 1 January 2025
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 17 (1) , 468-486
Open AccessA Review of Proteases and Antiproteases for Immune Regulation and Potential Therapeutic Application in Pulmonary Fibrosis
Background: Interstitial lung diseases (ILDs) or diffuse parenchymal lung diseases are general terms for a group of over 200 conditions that result from the destruction of cells neighbouring the alveoli, leading to extensive inflammation and fibrosis of the lungs. Although different types of ILD have distinct pathophysiology, clinical display, and advancement, many forms drive irreversible pulmonary fibrosis (PF), leading to progressive functional impairment, respiratory failure, and mortality. Summary: Key components of innate immunity include proteases and their cognate inhibitors, which are involved in respiratory homoeostasis. Alterations to the protease-antiprotease balance can lead to pulmonary disease and fibrotic scarring of the lungs, and over the past two decades, there has been a surge in research exploring their effect on the pathogenesis of ILDs. We have evaluated relevant studies regarding these enzymes in the context of lung fibrosis and have discussed prospects for developing novel treatments. This review will place greater emphasis on the overall effect of proteases and antiproteases to the development of PF, as studied using both in vivo and in vitro models. Key Message: Considering the limited therapeutic interventions, continued research on proteolytic enzymes and their inhibitors is required for the development of novel effective treatments for PF.
- Open Access
- 11 December 2024
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 17 (1) , 44-55
Does Adenosine Triphosphate via Purinergic Receptor Signalling Fuel Pulmonary Fibrosis?
Background: Interstitial lung diseases (ILD) are poorly understood disorders characterised by diffuse damage to the lung parenchyma, with inflammation and fibrosis. Some manifest a progressive fibrotic phenotype with high fatality and limited treatment options, such as idiopathic pulmonary fibrosis. Summary: The degree to which inflammation plays a role in fibrosis progression is unknown. However, wound healing and fibrosis are intricate processes influenced by various inflammatory factors. Extracellular nucleosides and nucleotides, including adenosine triphosphate, activate pro-inflammatory responses to innate immunity and are widely implicated in tissue fibrosis across different organs. The pro-inflammatory effects of extracellular nucleotides occur via P1 and P2 purinergic receptors, expressed across the lung and immune system, and have been implicated in various pulmonary diseases including pulmonary fibrosis. This review amalgamates available data on the complex role of P1 and P2 purinergic receptor signalling in pulmonary fibrosis and discusses perspectives for novel treatments. Key Messages: Purinergic signalling plays a complex and pivotal role in pulmonary fibrosis, warranting further study. The intricate interplay between P1 and P2 receptor pathways necessitates a comprehensive approach to understand their collective impact. While evidence from preclinical models is promising, human studies are essential for further understanding of pulmonary fibrosis. Advances in receptor-specific agonists and antagonists provide novel avenues for research and may ultimately lead to new therapies for patients.
- 11 December 2024
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 17 (1) , 44-55
Open AccessDoes Adenosine Triphosphate via Purinergic Receptor Signalling Fuel Pulmonary Fibrosis?
Background: Interstitial lung diseases (ILD) are poorly understood disorders characterised by diffuse damage to the lung parenchyma, with inflammation and fibrosis. Some manifest a progressive fibrotic phenotype with high fatality and limited treatment options, such as idiopathic pulmonary fibrosis. Summary: The degree to which inflammation plays a role in fibrosis progression is unknown. However, wound healing and fibrosis are intricate processes influenced by various inflammatory factors. Extracellular nucleosides and nucleotides, including adenosine triphosphate, activate pro-inflammatory responses to innate immunity and are widely implicated in tissue fibrosis across different organs. The pro-inflammatory effects of extracellular nucleotides occur via P1 and P2 purinergic receptors, expressed across the lung and immune system, and have been implicated in various pulmonary diseases including pulmonary fibrosis. This review amalgamates available data on the complex role of P1 and P2 purinergic receptor signalling in pulmonary fibrosis and discusses perspectives for novel treatments. Key Messages: Purinergic signalling plays a complex and pivotal role in pulmonary fibrosis, warranting further study. The intricate interplay between P1 and P2 receptor pathways necessitates a comprehensive approach to understand their collective impact. While evidence from preclinical models is promising, human studies are essential for further understanding of pulmonary fibrosis. Advances in receptor-specific agonists and antagonists provide novel avenues for research and may ultimately lead to new therapies for patients.
- 1 June 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 70 (6) , 524-527
Augmentation Therapy Decreases Platelet-Neutrophil Aggregates in Alpha-1 Antitrypsin Deficiency
- 1 June 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 70 (6) , 524-527
Augmentation Therapy Decreases Platelet-Neutrophil Aggregates in Alpha-1 Antitrypsin Deficiency
- 9 March 2023
- Published by European Respiratory Society (ERS)
- Vol. 9 (suppl 10) , 194
Peptidyl-arginine deiminases – neutrophil derived proteins as anti-Pseudomonas aeruginosa agents in patients with cystic fibrosis
Introduction:Pseudomonas aeruginosa is the major respiratory pathogen in patients with cystic fibrosis (CF). Chronic infections result in accelerated pulmonary function decline. New effective therapeutic options are needed. Proteomic studies have identified peptidyl-arginine deaminases (PADs) within neutrophil granules, possibly indicating their involvement in microbial killing. Aims: We hypothesised that PADs participate in the vacuolar bacterial killing process of neutrophils. To assess this, PAD’s in-vitro bactericidal effect against P. aeruginosa and localisation in neutrophils was evaluated. Methods: In bacterial killing assays, P. aeruginosa (PA01) was exposed to increasing concentrations of PAD2, PAD4 or bactericidal permeability-increasing protein (BPI; positive control) and colony-forming units or optical density (600 nm) were recorded. Subcellular fractionation of neutrophils was performed by sucrose gradient ultracentrifugation following N2 cavitation. Presence of PADs in neutrophil compartments was assessed by western blot analysis. Results: In combination, 20 nM PAD2 and PAD4 killed 74±19% of P. aeruginosa in 1hr (p < 0.001). Post-32 min exposure, PAD2, PAD4 and BPI exhibited MIC50 values of 18.9, 10.4, and 7.0 nM respectively. PAD2 and PAD4 were localised to neutrophil primary granules. Together these results support the antimicrobial participation of PADs following degranulation into neutrophil phagosomes. Conclusion: PAD2 and PAD4 possess potent anti-pseudomonal activity, warranting further research to validate the use of PAD-based antimicrobial agents for CF patients. This study was supported by Pfizer Healthcare Ireland.
- 9 March 2023
- Published by European Respiratory Society (ERS)
- Vol. 9 (suppl 10) , 194
Peptidyl-arginine deiminases – neutrophil derived proteins as anti-Pseudomonas aeruginosa agents in patients with cystic fibrosis
Introduction:Pseudomonas aeruginosa is the major respiratory pathogen in patients with cystic fibrosis (CF). Chronic infections result in accelerated pulmonary function decline. New effective therapeutic options are needed. Proteomic studies have identified peptidyl-arginine deaminases (PADs) within neutrophil granules, possibly indicating their involvement in microbial killing. Aims: We hypothesised that PADs participate in the vacuolar bacterial killing process of neutrophils. To assess this, PAD’s in-vitro bactericidal effect against P. aeruginosa and localisation in neutrophils was evaluated. Methods: In bacterial killing assays, P. aeruginosa (PA01) was exposed to increasing concentrations of PAD2, PAD4 or bactericidal permeability-increasing protein (BPI; positive control) and colony-forming units or optical density (600 nm) were recorded. Subcellular fractionation of neutrophils was performed by sucrose gradient ultracentrifugation following N2 cavitation. Presence of PADs in neutrophil compartments was assessed by western blot analysis. Results: In combination, 20 nM PAD2 and PAD4 killed 74±19% of P. aeruginosa in 1hr (p < 0.001). Post-32 min exposure, PAD2, PAD4 and BPI exhibited MIC50 values of 18.9, 10.4, and 7.0 nM respectively. PAD2 and PAD4 were localised to neutrophil primary granules. Together these results support the antimicrobial participation of PADs following degranulation into neutrophil phagosomes. Conclusion: PAD2 and PAD4 possess potent anti-pseudomonal activity, warranting further research to validate the use of PAD-based antimicrobial agents for CF patients. This study was supported by Pfizer Healthcare Ireland.
- Open Access
- 8 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6400
Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease
In the lung, glycosaminoglycans (GAGs) are dispersed in the extracellular matrix (ECM) occupying the interstitial space between the capillary endothelium and the alveolar epithelium, in the sub-epithelial tissue and in airway secretions. In addition to playing key structural roles, GAGs contribute to a number of physiologic processes ranging from cell differentiation, cell adhesion and wound healing. Cytokine and chemokine–GAG interactions are also involved in presentation of inflammatory molecules to respective receptors leading to immune cell migration and airway infiltration. More recently, pathophysiological roles of GAGs have been described. This review aims to discuss the biological roles and molecular interactions of GAGs, and their impact in the pathology of chronic airway diseases, such as cystic fibrosis and chronic obstructive pulmonary disease. Moreover, the role of GAGs in respiratory disease has been heightened by the current COVID-19 pandemic. This review underlines the essential need for continued research aimed at exploring the contribution of GAGs in the development of inflammation, to provide a better understanding of their biological impact, as well as leads in the development of new therapeutic agents.
- 8 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6400
Open AccessTargeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease
In the lung, glycosaminoglycans (GAGs) are dispersed in the extracellular matrix (ECM) occupying the interstitial space between the capillary endothelium and the alveolar epithelium, in the sub-epithelial tissue and in airway secretions. In addition to playing key structural roles, GAGs contribute to a number of physiologic processes ranging from cell differentiation, cell adhesion and wound healing. Cytokine and chemokine–GAG interactions are also involved in presentation of inflammatory molecules to respective receptors leading to immune cell migration and airway infiltration. More recently, pathophysiological roles of GAGs have been described. This review aims to discuss the biological roles and molecular interactions of GAGs, and their impact in the pathology of chronic airway diseases, such as cystic fibrosis and chronic obstructive pulmonary disease. Moreover, the role of GAGs in respiratory disease has been heightened by the current COVID-19 pandemic. This review underlines the essential need for continued research aimed at exploring the contribution of GAGs in the development of inflammation, to provide a better understanding of their biological impact, as well as leads in the development of new therapeutic agents.
- Top Cited PapersOpen Access
- 23 February 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2441
A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application
Alpha-1 antitrypsin (AAT) is the canonical serine protease inhibitor of neutrophil-derived proteases and can modulate innate immune mechanisms through its anti-inflammatory activities mediated by a broad spectrum of protein, cytokine, and cell surface interactions. AAT contains a reactive methionine residue that is critical for its protease-specific binding capacity, whereby AAT entraps the protease on cleavage of its reactive centre loop, neutralises its activity by key changes in its tertiary structure, and permits removal of the AAT-protease complex from the circulation. Recently, however, the immunomodulatory role of AAT has come increasingly to the fore with several prominent studies focused on lipid or protein-protein interactions that are predominantly mediated through electrostatic, glycan, or hydrophobic potential binding sites. The aim of this review was to investigate the spectrum of AAT molecular interactions, with newer studies supporting a potential therapeutic paradigm for AAT augmentation therapy in disorders in which a chronic immune response is strongly linked.
- 23 February 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (5) , 2441
Top Cited PapersOpen AccessA Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application
Alpha-1 antitrypsin (AAT) is the canonical serine protease inhibitor of neutrophil-derived proteases and can modulate innate immune mechanisms through its anti-inflammatory activities mediated by a broad spectrum of protein, cytokine, and cell surface interactions. AAT contains a reactive methionine residue that is critical for its protease-specific binding capacity, whereby AAT entraps the protease on cleavage of its reactive centre loop, neutralises its activity by key changes in its tertiary structure, and permits removal of the AAT-protease complex from the circulation. Recently, however, the immunomodulatory role of AAT has come increasingly to the fore with several prominent studies focused on lipid or protein-protein interactions that are predominantly mediated through electrostatic, glycan, or hydrophobic potential binding sites. The aim of this review was to investigate the spectrum of AAT molecular interactions, with newer studies supporting a potential therapeutic paradigm for AAT augmentation therapy in disorders in which a chronic immune response is strongly linked.